Moderna, Inc. $MRNA Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 74.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 168,077 shares of the company’s stock after buying an additional 71,888 shares during the quarter. Quantinno Capital Management LP’s holdings in Moderna were worth $8,538,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital World Investors purchased a new position in shares of Moderna in the 4th quarter worth $378,299,000. Alyeska Investment Group L.P. purchased a new stake in Moderna during the fourth quarter valued at about $95,209,000. Norges Bank purchased a new stake in Moderna during the fourth quarter valued at about $79,707,000. Invesco Ltd. increased its stake in Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after acquiring an additional 1,115,131 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Moderna by 123.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,788,951 shares of the company’s stock worth $52,775,000 after acquiring an additional 987,312 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MRNA. The Goldman Sachs Group raised their price objective on Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a report on Tuesday, July 21st. Bank of America increased their target price on shares of Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. Morgan Stanley raised their price target on shares of Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Wolfe Research reaffirmed an “underperform” rating and set a $25.00 price target on shares of Moderna in a research report on Monday, July 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $42.13.

Moderna Stock Up 3.5%

Shares of NASDAQ MRNA opened at $57.08 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $85.60. The stock’s 50-day simple moving average is $59.74 and its 200-day simple moving average is $52.87. The firm has a market cap of $22.79 billion, a price-to-earnings ratio of -7.14 and a beta of 0.91.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the prior year, the business posted ($2.13) earnings per share. Moderna’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, equities analysts anticipate that Moderna, Inc. will post -6.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 119,406 shares of company stock valued at $5,928,762 in the last three months. Corporate insiders own 10.80% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna administered the first doses in a Phase 1 trial of mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus. The strain has no licensed vaccine, and the study will assess safety and immune response in Canada following Health Canada authorization. The program, developed with support from the Coalition for Epidemic Preparedness Innovations, highlights the potential speed and flexibility of Moderna’s mRNA platform. Moderna begins first human trial of Bundibugyo Ebola vaccine
• Positive Sentiment: Investors viewed the Ebola program as a potential long-term opportunity, particularly because a deadly outbreak has increased demand for protection against the virus and there is currently no approved vaccine for this strain. However, the candidate is only entering Phase 1, so any commercial benefit remains uncertain and several years away. Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
• Neutral Sentiment: Brookline Capital Markets modestly improved its 2026 quarterly and full-year loss estimates, forecasting a $6.60 per-share loss for 2026 versus its prior $7.26 estimate. The firm still expects losses in 2027, though its forecast deteriorated sharply to a $3.24 per-share loss from a previous $0.08 loss, signaling limited near-term profitability visibility.
• Negative Sentiment: Moderna’s Phase 3 norovirus vaccine trial showed no early success, raising concerns about another potential setback in the company’s pipeline and increasing reliance on its respiratory vaccine franchise and earlier-stage programs. No early success for Moderna’s norovirus vaccine in phase 3 trial

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.